Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Depreciation and Depletion: 2019-2025

Historic Depreciation and Depletion for Puma Biotechnology (PBYI) over the last 7 years, with Sep 2025 value amounting to $100,000.

  • Puma Biotechnology's Depreciation and Depletion changed negligibly% to $100,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $400,000, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $400,000 for FY2024, which is negligibly% changed negligibly from last year.
  • Latest data reveals that Puma Biotechnology reported Depreciation and Depletion of $100,000 as of Q3 2025, which was down 0.00% from $100,000 recorded in Q2 2025.
  • Puma Biotechnology's Depreciation and Depletion's 5-year high stood at $200,000 during Q1 2021, with a 5-year trough of $100,000 in Q4 2021.
  • Over the past 3 years, Puma Biotechnology's median Depreciation and Depletion value was $100,000 (recorded in 2025), while the average stood at $100,000.
  • Data for Puma Biotechnology's Depreciation and Depletion shows a maximum YoY crashed of 50.00% (in 2021) over the last 5 years.
  • Over the past 5 years, Puma Biotechnology's Depreciation and Depletion (Quarterly) stood at $100,000 in 2021, then remained steady at $100,000 in 2022, then remained steady at $100,000 in 2023, then remained steady at $100,000 in 2024, then remained steady at $100,000 in 2025.
  • Its Depreciation and Depletion was $100,000 in Q3 2025, compared to $100,000 in Q2 2025 and $100,000 in Q1 2025.